Bank of New York Mellon Corp Increases Holdings in UroGen Pharma Ltd. (NASDAQ:URGN)

Bank of New York Mellon Corp increased its holdings in shares of UroGen Pharma Ltd. (NASDAQ:URGN) by 41.6% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 96,619 shares of the company’s stock after purchasing an additional 28,400 shares during the period. Bank of New York Mellon Corp owned 0.41% of UroGen Pharma worth $1,621,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently added to or reduced their stakes in URGN. RTW Investments LP boosted its position in UroGen Pharma by 101.4% in the 4th quarter. RTW Investments LP now owns 1,726,808 shares of the company’s stock valued at $25,902,000 after buying an additional 869,344 shares during the last quarter. Price T Rowe Associates Inc. MD acquired a new stake in shares of UroGen Pharma in the first quarter valued at approximately $4,008,000. Superstring Capital Management LP acquired a new stake in shares of UroGen Pharma in the fourth quarter valued at approximately $3,831,000. Oak Ridge Investments LLC acquired a new stake in shares of UroGen Pharma in the first quarter valued at approximately $918,000. Finally, Wellington Management Group LLP boosted its holdings in shares of UroGen Pharma by 49.3% in the fourth quarter. Wellington Management Group LLP now owns 104,600 shares of the company’s stock valued at $1,569,000 after acquiring an additional 34,537 shares in the last quarter. 91.29% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of analysts recently weighed in on URGN shares. HC Wainwright restated a “buy” rating and set a $60.00 target price on shares of UroGen Pharma in a report on Wednesday, August 14th. Guggenheim initiated coverage on shares of UroGen Pharma in a research note on Thursday, August 22nd. They issued a “buy” rating and a $40.00 price objective for the company. LADENBURG THALM/SH SH lifted their price objective on shares of UroGen Pharma from $48.00 to $53.50 and gave the company a “buy” rating in a research note on Friday, June 14th. Finally, Oppenheimer boosted their target price on shares of UroGen Pharma from $32.00 to $40.00 and gave the stock an “outperform” rating in a research report on Friday, June 14th.

UroGen Pharma Stock Performance

NASDAQ:URGN opened at $13.10 on Thursday. The company has a market cap of $307.20 million, a price-to-earnings ratio of -3.85 and a beta of 1.11. The firm’s 50-day moving average is $14.95 and its 200-day moving average is $14.85. UroGen Pharma Ltd. has a 52-week low of $10.60 and a 52-week high of $20.70. The company has a debt-to-equity ratio of 3.23, a quick ratio of 7.93 and a current ratio of 8.15.

UroGen Pharma (NASDAQ:URGN) last posted its earnings results on Tuesday, August 13th. The company reported ($0.91) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.82) by ($0.09). The company had revenue of $21.85 million for the quarter, compared to analyst estimates of $23.69 million. Equities research analysts anticipate that UroGen Pharma Ltd. will post -3.49 earnings per share for the current year.

UroGen Pharma Profile

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.